Last reviewed · How we verify
Otsuka Pharmaceutical, Inc., Philippines — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Rebamipide and Esomeprazole | Rebamipide and Esomeprazole | marketed | Mucoprotective agent + Proton pump inhibitor combination | Rebamipide: gastric mucosa protective mechanisms; Esomeprazole: H+/K+-ATPase | Gastroenterology |
Therapeutic area mix
- Gastroenterology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Otsuka Pakistan Limited · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Otsuka Pharmaceutical, Inc., Philippines:
- Otsuka Pharmaceutical, Inc., Philippines pipeline updates — RSS
- Otsuka Pharmaceutical, Inc., Philippines pipeline updates — Atom
- Otsuka Pharmaceutical, Inc., Philippines pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Otsuka Pharmaceutical, Inc., Philippines — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/otsuka-pharmaceutical-inc-philippines. Accessed 2026-05-17.